ST. LOUIS, MO--(Marketwire - June 01, 2010) - ISTO Technologies, Inc. announced today that it will participate in the Jefferies 2010 Global Life Sciences Conference to be held in New York, NY on June 8-11, 2010. Mitchell Seyedin, Ph.D., President and CEO, is scheduled to provide a 30-minute overview of the Company at 8:30 a.m. Eastern Time on Thursday, June 10th. The conference will feature presentations from over 300 leading public and private healthcare companies across the life sciences spectrum, including biotechnology, life science tools, medical devices, diagnostics, specialty pharmaceuticals, and multi-national pharmaceutical companies.
The Company's leading cartilage regeneration product, DeNovo® ET, is a scaffold-free engineered cartilage tissue derived from expanded juvenile chondrocytes and is currently in human clinical trials for the repair of injured knee joints as an investigational product.
ISTO's second cell-based product in development, NuQu™, is an injectable formulation of juvenile cartilage cells intended for regeneration and repair of tissue lost to chronic disc diseases. NuQu is intended for minimally invasive intervention for patients suffering from discogenic back pain. ISTO commenced a Phase I clinical trial for NuQu under an IND approval from the FDA in early 2010.
In addition to ISTO's clinical-stage cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute. InQu contains integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications.
ISTO is a privately-held orthobiologics Company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.